YWYinghan Wang

Yinghan Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yinghan Wang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Chunying Li

    Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi’an, China

    3 shared publications
  • Shuli Li

    Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi’an, China

    3 shared publications
  • Pan Kang

    Department of Dermatology, Xijing Hospital, Fourth Military Medical University, No. 127 of West Changle Road, Xi’an, Shaanxi 710032, China

    2 shared publications
  • Tingting Cui

    Xinjiang Key Laboratory of Molecular Biology for Endemic Diseases, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, School of Basic Medical Sciences, Xinjiang Medical University, Urumqi 830017, China

    2 shared publications
  • Xiuli Yi

    Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China

    2 shared publications
  • Huina Wang

    Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China

    1 shared publication

Latest Publications

  • TRPM2 ‐dependent autophagy inhibition exacerbates oxidative stress‐induced CXCL16 secretion by keratinocytes in vitiligo

    by Pan Kang, Yinghan Wang, Jianru Chen, Yuqian Chang, Weigang Zhang, Tingting Cui, Xiuli Yi, Shuli Li, Chunying Li

    Vitiligo is a depigmented skin disease due to the destruction of melanocytes. Under oxidative stress, keratinocyte‐derived chemokine C‐X‐C motif ligand 16 (CXCL16) plays a critical role in recruiting CD8 + T cells, which kill melanocytes. Autophagy serves as a protective cell survival mechanism and impairment of autophagy has been linked to increased secretion of the proinflammatory cytokines. However, the role of autophagy in the secretion of CXCL16 under oxidative stress has not been investigated. Herein, we initially found that autophagy was suppressed in both keratinocytes of vitiligo lesions and keratinocytes exposed to oxidative stress in vitro . Autophagy inhibition also promoted CXCL16 secretion. Furthermore, upregulated transient receptor potential cation channel subfamily M member 2 (TRPM2) functioned as an upstream oxidative stress sensor to inhibit autophagy. Moreover, TRPM2‐mediated Ca 2+ influx activated calpain to shear autophagy related 5 (Atg5) and Atg12–Atg5 conjugate formation was blocked to inhibit autophagy under oxidative stress. More importantly, Atg5 downregulation enhanced the binding of interferon regulatory factor 3 (IRF3) to the CXCL16 promoter region by activating Tank‐binding kinase 1 (TBK1), thus promoting CXCL16 secretion. These findings suggested that TRPM2‐restrained autophagy promotes CXCL16 secretion via the Atg5‐TBK1‐IRF3 signaling pathway under oxidative stress. Inhibition of TRPM2 may serve as a potential target for the treatment of vitiligo. © 2024 The Pathological Society of Great Britain and Ireland.


  • HSF1-Dependent Autophagy Activation Contributes to the Survival of Melanocytes Under Oxidative Stress in Vitiligo

    by Tingting Cui, Yinghan Wang, Pu Song, Xiuli Yi, Jiaxi Chen, Yuqi Yang, Huina Wang, Pan Kang, Sen Guo, Ling Liu, et al.


  • Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo

    by Yinghan Wang, Shuli Li, Chunying Li

    Vitiligo is an autoimmune disease of the skin characterized by epidermal melanocyte loss resulting in white patches, with an approximate prevalence of 0.5–2% worldwide. Several precipitating factors by chemical exposure and skin injury present commonly in patients with vitiligo. Although the diagnosis appears to be straightforward for the distinct clinical phenotype and specific histological features, vitiligo provides many challenges including chronicity, treatment resistance, frequent relapse, associated profound psychosocial effect, and negative impact on quality of life. Multiple mechanisms are involved in melanocyte disappearance, including genetics, environmental factors, and immune-mediated inflammation. Compelling evidence supports the melanocyte intrinsic abnormalities with poor adaptation to stressors leading to instability and release of danger signals, which will activate dendritic cells, natural killer cells, and innate lymphoid cells to initiate innate immunity, ultimately resulting in T-cell mediated adaptive immune response and melanocyte destruction. Importantly, the cross- talk between keratinocytes, melanocytes, and immune cells, such as interferon (IFN)-γ signaling pathway, builds inflammatory loops that give rise to the disease deterioration. Improved understanding of the immune pathogenesis of vitiligo has led to the development of new therapeutic options including Janus kinase (JAK) inhibitors targeting IFN-γ signaling pathways, which can effectively reverse depigmentation. Furthermore, definition of treatment goals and integration of comorbid diseases into vitiligo management have revolutionized the way vitiligo is treated. In this review, we highlight recent developments in vitiligo clinical aspects and immune pathogenesis. Our key objective is to raise awareness of the complexity of this disease, the potential of prospective therapy strategies, and the need for early and comprehensive management.